<DOC>
	<DOCNO>NCT02631616</DOCNO>
	<brief_summary>Purpose : Castrate resistance prostate cancer ( CRPC ) often show histological evidence neuroendocrine differentiation ( NED ) . Recently investigator initiate research project investigate uptake radiotracer 68Ga-DOTATET ( marker neuroendocrine tumors-NET ) PET/CT patient CRPC . In 4/8 patient study thus far , uptake tracer bone metastases find . It show monthly injection Somatostatin lengthen overall survival patient NET . The purpose current project examine ability Somatostatin stabilize possibly reverse metastasis patient CRPC express high level somatostatin receptor 68Ga-DOTATET PET/CT . Materials Methods : 30 patient CRPC study 68Ga-DOTATET PET/CT . Patients show uptake radiotracer 68Ga-DOTATET two least metastasis consider eligible study . These patient evaluate biochemically clinically treat monthly injection Sandoatatin LAR - 30mg . Clinical , biochemical imaging study ( 68Ga-DOTATET PET/CT ) repeat 4 12 month treatment . Responding patient ( stabilization decrease number SUV metastasis ) subject continued therapy progression .</brief_summary>
	<brief_title>Treatment With Sandostatin Patients With Castrate Resistance Prostate Cancer Showing Uptake 68Ga-DOTATET</brief_title>
	<detailed_description>Introduction : Neuroendocrine tumor ( NET ) present receptor somatostatin . This feature utilize therapeutically patient metastatic NET . Monthly injection Somatostatin show lengthen overall survival ( compare placebo ) patient . From histological study know advanced prostate cancer often show neuroendocrine differentiation ( NED ) . This consider one mechanism `` escape '' tumor cell androgen deprivation therapy . Recently investigatros initiated research project investigate uptake radiotracer 68Ga-DOTATET ( marker neuroendocrine tumors-NET ) PET/CT patient castrate resistance prostate cancer . In 4/8 patient study thus far , uptake tracer bone metastases find . Purpose : The purpose current project examine ability LAR Somatostatin stabilize possibly reverse metastasis patient castrate resistance prostate cancer express high level somatostatin receptor . The aim study : 1 . To detect biochemical response ( PSA chromogranin A ) 2 . To detect PET response ( repeat PET/CT , 68Ga-DOTATET ) . 3 . To detect clinical response ( QOL 30 questioner ) . 4 . To detect adverse response . Materials Methods : 1 . Eligible patient evaluate : serum level PSA , chromogranin A , Pro GRP possibly non-genetic marker QOL 30 questioner 2 . Treatment monthly injection Sandoatatin LAR - 30mg initiate . 3 . Evaluation do 4 injection include : blood test PSA chromogranin A , Pro GRP possibly non-genetic marker QOL 30 questioner PET/CT 68Ga-DOTATET . Similar evaluation do 12 injection . Responding patient ( stabilization decrease number SUV metastasis ) subject continued therapy progression .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Somatostatin</mesh_term>
	<mesh_term>Octreotide</mesh_term>
	<criteria>1 . Patients histologically proven prostate cancer . 2 . Hormonal treatment ( either surgical orchiectomy medical castration LHRH agonist antagonist ) . 3 . Proven castration level ( serum Testosterone &lt; 50 ng/dl ) 4 . Radiological evidence metastatic disease . 5 . Uptake radiotracer 68GaDOTATET two least metastasis . 1 . Participation another trial .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2015</verification_date>
	<keyword>Prostatic Neoplasma , Castration-Resistant</keyword>
	<keyword>neuroendocrine differentiation</keyword>
	<keyword>68Ga-DOTATET</keyword>
	<keyword>PET/CT</keyword>
</DOC>